CorMedix price target raised to $12 from $11 at RBC Capital

TipRanks12-20 20:21

RBC Capital raised the firm’s price target on CorMedix (CRMD) to $12 from $11 and keeps an Outperform rating on the shares. The company has had a productive 2024 with the launch of DefenCath ongoing, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492448157?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4SmA9KoGNomql4gwxNxdZw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6","is_english":true,"pubTime":"2024-12-20 20:21","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492448157","market":"us","top_or_hot":-1,"title":"CorMedix price target raised to $12 from $11 at RBC Capital","media":"TipRanks","content":"<div>\n<p>RBC Capital raised the firm’s price target on CorMedix (CRMD) to $12 from $11 and keeps an Outperform rating on the shares. The company has had a productive 2024 with the launch of DefenCath ongoing, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cormedix-price-target-raised-12-122101125.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix price target raised to $12 from $11 at RBC Capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix price target raised to $12 from $11 at RBC Capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 20:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cormedix-price-target-raised-12-122101125.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>RBC Capital raised the firm’s price target on CorMedix (CRMD) to $12 from $11 and keeps an Outperform rating on the shares. The company has had a productive 2024 with the launch of DefenCath ongoing, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cormedix-price-target-raised-12-122101125.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/cormedix-price-target-raised-12-122101125.html","article_id":"2492448157","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4SmA9KoGNomql4gwxNxdZw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cormedix-price-target-raised-12-122101125.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2492448157","pubTimestamp":1734697261,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"RBC Capital raised the firm’s price target on CorMedix  to $12 from $11 and keeps an Outperform rating on the shares. The company has had a productive 2024 with the launch of DefenCath ongoing, and the management has remained in execution mode, establishing commercial agreements with dialysis providers and operators, including the signing of a large dialysis organization, the analyst tells investors in a research note. As DefenCath’s launch matures, RBC sees signs of reduced ordering and logistical friction, along with favorable economics, the firm added.Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks. Alphabet, AMD report Q3 earnings beats: Morning Buzz","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc."},"translate_title":"RBC Capital将CorMedix目标价从11美元上调至12美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":0.9},"content_text":"RBC Capital raised the firm’s price target on CorMedix (CRMD) to $12 from $11 and keeps an Outperform rating on the shares. The company has had a productive 2024 with the launch of DefenCath ongoing, and the management has remained in execution mode, establishing commercial agreements with dialysis providers and operators, including the signing of a large dialysis organization, the analyst tells investors in a research note. As DefenCath’s launch matures, RBC sees signs of reduced ordering and logistical friction, along with favorable economics, the firm added.\n\nPick the best stocks and maximize your portfolio:\n\nDiscover top-rated stocks from highly ranked analysts with Analyst Top Stocks!\nEasily identify outperforming stocks and invest smarter with Top Smart Score Stocks\n\n\n\nPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>\n\n\nSee today’s best-performing stocks on TipRanks >>\n\n\nRead More on CRMD:\n\nCorMedix supports CMS policy updates\nCorMedix Approves Key Governance and Incentive Changes\nCorMedix Inc. Reports Q3 2024 Financial Results\nAlphabet, AMD report Q3 earnings beats: Morning Buzz\nCorMedix reports Q3 EPS (5c), consensus (10c)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492448157"}